The development of in vivo biomarkers of Alzheimer's disease (AD) has advanced the
diagnosis of AD from a clinical syndrome to a biological construct. The preclinical stage of …

The potential existence and roles of the meningeal lymphatic system in normal and
pathological brain function have been a long-standing enigma. Recent evidence suggests …

Abstract Background In China, an increasing number of people are aging; therefore,
attention should be paid to age-related cognitive impairment. With the increasing attention …

Background and Objectives To investigate the prevalence and trajectories of
neuropsychiatric symptoms (NPS) in relation to cognitive functioning in a cohort of β-amyloid …

Introduction Cognitive impairment is the hallmark of Alzheimer's disease (AD) and related
dementias. However, motor decline has been recently described as a prodromal state that …

Introduction Mild behavioral impairment (MBI) is characterized by later‐life emergence of
neuropsychiatric symptoms. Investigating its relationship with progression to Alzheimer's …

Background To operationalize the National Institute on Aging–Alzheimer's Association (NIA‐
AA) Research Framework for Alzheimer's Disease 6‐stage continuum of clinical progression …

Background Prescribing benzodiazepines to older patients is controversial. Anxiety
disorders and benzodiazepines have been associated with dementia, but literature is …

Abstract Mild Behavioral Impairment (MBI) leverages later-life emergent and persistent
neuropsychiatric symptoms (NPS) to identify a high-risk group for incident dementia …

Background: While the gender/sex differences in neuropsychiatric symptoms in dementia
population are well described, gender/sex differences in mild behavioral impairment (MBI) in …